Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease

• Published in: The New England journal of medicine Vol. 378; no. 4; pp. 321 - 330
• Main Authors: Honig, Lawrence S, Vellas, Bruno, Woodward, Michael, Boada, Mercè, Bullock, Roger, Borrie, Michael, Hager, Klaus, Andreasen, Niels, Scarpini, Elio, Liu-Seifert, Hong, Case, Michael, Dean, Robert A, Hake, Ann, Sundell, Karen, Poole Hoffmann, Vicki, Carlson, Christopher, Khanna, Rashna, Mintun, Mark, DeMattos, Ronald, Selzler, Katherine J, Siemers, Eric
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 25.01.2018
• Subjects: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease - diagnosis; Alzheimer Disease - drug therapy; Alzheimer Disease - psychology; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Biomarkers; Biomarkers - cerebrospinal fluid; Brain research; Cerebrospinal fluid; Clinical trials; Cognitive ability; Dementia; Dementia disorders; Double-Blind Method; Edema; Effusion; Female; Geriatrics; Humans; Immunotherapy; Infusions, Intravenous; Magnetic resonance imaging; Male; Mental Status and Dementia Tests; Middle Aged; Monoclonal antibodies; Neurodegenerative diseases; Neurofibrillary tangles; Neuroimaging; Patients; Peptide Fragments - cerebrospinal fluid; Plaque, Amyloid - drug therapy; Positron emission tomography; Proteins; Senile plaques; Synapses; Treatment Failure
• ISSN: 0028-4793; 1533-4406; 1533-4406
• DOI: 10.1056/NEJMoa1705971

In a randomized trial, solanezumab, a humanized monoclonal antibody against soluble amyloid, did not slow cognitive decline over a period of 80 weeks in patients with mild Alzheimer’s disease and with PET or CSF biomarkers of amyloid-related disease.